Search for Clinical Trial Results
Blast Crisis - 25 Studies Found
Status | Study |
Completed |
Study Name: Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Condition:
Date: 2005-01-12 Interventions: Drug: Dasatinib Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, sw |
Completed |
Study Name: BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia Condition:
Date: 2005-02-14 Interventions: Drug: Dasatinib Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response. |
Completed |
Study Name: Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia Condition: Leukemia Date: 2008-12-31 Interventions:
|
Completed |
Study Name: PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome Condition:
|
Recruiting |
Study Name: An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Condition: Leukemia Date: 2011-12-21 Interventions:
|